On March 17, GT Advanced Technologies Inc (NASDAQ:GTAT) got buy rating from Canaccord Genuity emphasizing its’s shares and potential opportunities. GT Advanced Technologies Inc (NASDAQ:GTAT) shares after opening at $18.63 moved to $18.63 on last trade day and at the end of the day closed at $17.87. Company price to sales ratio in past twelve months was calculated as 7.53 and price to cash ratio as 4.52. GT Advanced Technologies Inc (NASDAQ:GTAT) showed a positive weekly performance of 4.20%.
Nu Skin Enterprises (NYSE:NUS) saw strong trading volume on Monday after Canaccord Genuity raised their price target on the stock from $78.00 to $93.00, Stock Ratings News reports. Nu Skin Enterprises, Inc.(NYSE:NUS) shares advanced 18.21% in last trading session and ended the day on $88.66. NUS return on equity ratio is recorded as 43.10% and its return on assets is 20.50%. Nu Skin Enterprises, Inc.(NYSE:NUS) yearly performance is 109.20%.
Stock analysts at Macquarie initiated coverage on shares of Ubiquiti Networks (NASDAQ:UBNT) in a report issued on Thursday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock. Ubiquiti Networks Inc (NASDAQ:UBNT) shares moved down -8.30% in last trading session and was closed at $50.19, while trading in range of $48.60 – 54.95 . Ubiquiti Networks Inc(NASDAQ:UBNT) year to date (YTD) performance is 9.20%.
Shares of Clovis Oncology (NASDAQ:CLVS) have been given a consensus rating of “Buy” by the seven analysts that are covering the company, Analyst Ratings.Net reports. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $90.40. Clovis Oncology Inc (NASDAQ:CLVS) weekly performance is -9.64%. On last trading day company shares ended up $73.52. Clovis Oncology Inc (NASDAQ:CLVS) distance from 50-day simple moving average (SMA50) is -1.42%. Analysts mean target price for the company is $101.17.